Multiple Sclerosis is a lifelong autoimmune condition that affects the central nervous system, specifically the brain and spinal cord. In this condition, the immune system mistakenly attacks the protective sheath called myelin that surrounds nerve fibres. This damage causes inflammation and creates scar tissue, known as sclerosis, which disrupts the electrical signals travelling between the brain and the rest of the body.
In 2026, Multiple Sclerosis is understood as a highly individual condition; while some people experience mild symptoms, others may face significant challenges with mobility, vision, and cognitive function. Although there is currently no cure, modern treatments in the UK have advanced significantly, offering better ways to manage the disease and slow its progression than ever before.
What we will discuss in this article
- The biological process of demyelination and the immune response
- Recognizing common symptoms like optic neuritis and fatigue
- The three main types: Relapsing Remitting, Primary Progressive, and Secondary Progressive
- Modern diagnostic tools including MRI and lumbar punctures
- Latest 2026 NHS treatment updates and natalizumab recommendations
- Long term management through multidisciplinary care teams
- Emergency guidance for acute neurological changes
Symptoms and early signs
Symptoms vary widely depending on which part of the central nervous system is affected, but several focal signs are common during early presentation.
One of the most frequent early indicators is optic neuritis, which causes painful loss of vision in one eye, blurred vision, or flashes of light. Other common symptoms include persistent numbness or tingling in the limbs, unexplained muscle weakness, and difficulties with balance or coordination. Many patients also experience overwhelming fatigue, which is often described as a sense of weariness that makes even simple mental or physical tasks difficult. Bladder and bowel problems, as well as cognitive changes like difficulty concentrating or remembering new information, are also significant features that patients may encounter.
The three main types of Multiple Sclerosis
Clinicians categorize the condition based on how the symptoms develop and progress over time.
Relapsing Remitting
This is the most common form, affecting about 85 percent of those diagnosed. It is characterised by distinct attacks or relapses where symptoms suddenly worsen, followed by periods of remission where they fade away partially or completely. Over many years, this type may transition into a progressive phase.
Primary Progressive
In this form, symptoms gradually worsen, and disability accumulates from the very beginning, without distinct periods of relapse or remission. It affects about 10 to 15 per cent of patients and is typically diagnosed in people in their 40s or 50s.
Secondary Progressive
This stage can follow relapsing remitting. It involves a steady worsening of disability that occurs independently of any specific relapses. Modern disease modifying therapies aim to delay the onset of this stage for as long as possible.
2026 Treatment breakthroughs
The treatment landscape in the UK has reached new milestones in early 2026, providing more options for those with highly active disease.
In January, 2026, NICE issued new guidance recommending natalizumab as a treatment option for adults with highly active relapsing remitting Multiple Sclerosis who have not responded to at least one other therapy. This includes both the original version and a newer biosimilar version. Natalizumab is highly effective at stopping inflammatory immune cells from entering the brain. Another groundbreaking development occurred in late 2025, when the first UK patient was treated with CAR T cell therapy in a clinical trial. This experimental treatment aims to reset the immune system by depleting the B cells that drive the autoimmune attack, potentially leading to long term remission.
Diagnosis and management
Confirming a diagnosis involves ruling out other conditions and using specialized imaging.
The primary diagnostic tool is an MRI scan of the brain and spinal cord, which can identify areas of inflammation or scarring known as lesions. Doctors may also perform a lumbar puncture to check the spinal fluid for specific proteins called oligoclonal bands. Management is typically led by a multidisciplinary team, including a consultant neurologist and a specialist nurse. This team works together to prescribe disease modifying therapies, manage symptoms with muscle relaxants or pain medication, and provide supportive therapies like physiotherapy or cognitive behavioural therapy.
Emergency guidance
While this is a chronic condition, sudden or rapidly developing neurological symptoms require urgent clinical assessment to rule out other serious events like a stroke.
Seek immediate medical help if you experience a sudden onset of weakness or numbness on one side of the face or body, as this may be a medical emergency.
Seek urgent medical advice if you notice:
- Sudden loss of vision or severe eye pain
- Rapid onset of severe balance problems or dizziness
- A significant and disabling change in your ability to walk or move
- Signs of a severe infection, such as a high fever with intense confusion
- Rapidly worsening respiratory distress or difficulty swallowing
To summarise
Multiple Sclerosis is a complex autoimmune disorder where the body attacks its own nervous system, leading to a wide range of motor, sensory, and cognitive symptoms. In 2026, the focus of UK clinical care is on early diagnosis and the rapid introduction of highly effective disease-modifying therapies to prevent long term disability. With three distinct types and a variety of individual presentations, personalised care from a specialist team is essential. Recent breakthroughs in medications like natalizumab and experimental CAR T cell trials offer significant hope for patients, aiming to provide a better quality of life and more control over the progression of the condition.
Can Multiple Sclerosis be cured?
Currently, there is no cure, but treatments have become highly effective at reducing the frequency of relapses and slowing down the accumulation of disability.
Is it hereditary?
It is not directly inherited, but having a parent or sibling with the condition slightly increases your risk, suggesting a combination of genetic and environmental factors.
What is a biosimilar medicine?
A biosimilar is a newer version of a biological medicine that works in the same way as the original. In 2026, the NHS is using biosimilars to provide high quality treatment to more patients.
Does heat make symptoms worse?
Yes, many people find that their symptoms temporarily worsen with heat, a phenomenon known as Uhthoff’s sign. This is usually temporary and not a sign of a new relapse.
What is the difference between a relapse and a progression?
A relapse is a sudden flare up of new or old symptoms that lasts at least 24 hours. Progression refers to a steady, gradual worsening of symptoms over at least six months.
Can I still work?
Many people continue to work for many years. Occupational therapists can help suggest adaptations to your workspace or schedule to help you manage fatigue and other symptoms.
Why is Vitamin D mentioned?
Low levels of Vitamin D have been linked to an increased risk of development and a higher frequency of relapses, so many UK clinicians recommend monitoring and supplementing Vitamin D.
Authority Snapshot
This article was reviewed by Dr. Rebecca Fernandez, a UK trained physician with an MBBS and extensive experience in internal medicine, neurology, and emergency care. Her background includes the management of acute trauma and the stabilization of critically ill patients, alongside a deep focus on evidence based approaches to mental well being. Dr. Fernandez is dedicated to helping patients understand the complexities of neurological health to ensure safe, effective, and holistic long term care.
